COFG Advisors LLC Buys Shares of 2,615 Johnson & Johnson $JNJ

COFG Advisors LLC bought a new stake in Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,615 shares of the company’s stock, valued at approximately $541,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Sage Investment Advisers LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter worth about $1,052,000. Colton Groome Financial Advisors LLC grew its holdings in Johnson & Johnson by 6.5% during the 4th quarter. Colton Groome Financial Advisors LLC now owns 1,762 shares of the company’s stock worth $365,000 after acquiring an additional 108 shares during the last quarter. Brentview Investment Management LLC grew its holdings in Johnson & Johnson by 1.3% during the 4th quarter. Brentview Investment Management LLC now owns 26,597 shares of the company’s stock worth $5,504,000 after acquiring an additional 331 shares during the last quarter. New Mexico Educational Retirement Board grew its holdings in Johnson & Johnson by 2.8% during the 4th quarter. New Mexico Educational Retirement Board now owns 111,685 shares of the company’s stock worth $23,113,000 after acquiring an additional 3,000 shares during the last quarter. Finally, Peapack Gladstone Financial Corp grew its holdings in Johnson & Johnson by 0.3% during the 4th quarter. Peapack Gladstone Financial Corp now owns 431,229 shares of the company’s stock worth $89,243,000 after acquiring an additional 1,169 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on JNJ shares. Weiss Ratings downgraded shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b)” rating in a research report on Friday, April 24th. Sanford C. Bernstein upped their target price on shares of Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a research report on Wednesday, April 15th. Daiwa Securities Group upped their target price on shares of Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a research report on Thursday, April 16th. Guggenheim upped their target price on shares of Johnson & Johnson from $244.00 to $266.00 and gave the company a “buy” rating in a research report on Monday, April 20th. Finally, Bank of America upped their target price on shares of Johnson & Johnson from $253.00 to $254.00 and gave the company a “neutral” rating in a research report on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $253.04.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson announced strong late-stage prostate cancer data for ERLEADA (apalutamide), showing it significantly reduced the risk of metastasis or death and improved key surgical outcomes. The results, presented at ASCO and published in The New England Journal of Medicine, could strengthen the drug’s commercial outlook. Article Title
• Positive Sentiment: J&J also reported pivotal data for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) in advanced head and neck cancer, with durable responses and a meaningful complete-response rate. The company has already submitted for FDA approval in this indication, which could expand its oncology pipeline. Article Title
• Positive Sentiment: Separate coverage highlighted Johnson & Johnson as one of the best dividend-paying stocks to buy right now, reinforcing its appeal as a defensive income name for investors seeking stability and yield. Article Title
• Neutral Sentiment: Another article asked whether J&J is too expensive after its 48% one-year surge, reflecting valuation concerns rather than a direct change in fundamentals. The piece suggests some investors may be pausing after the stock’s strong rally. Article Title
• Negative Sentiment: Recent commentary also noted the stock has slipped in the short term, implying some near-term profit-taking as investors digest the large year-to-date move and weigh whether upside is already reflected in the price. Article Title

Johnson & Johnson Trading Down 0.6%

JNJ stock opened at $223.90 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The company has a fifty day moving average price of $232.75 and a two-hundred day moving average price of $225.29. Johnson & Johnson has a one year low of $149.04 and a one year high of $251.71. The stock has a market cap of $538.96 billion, a price-to-earnings ratio of 25.88, a price-to-earnings-growth ratio of 2.21 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. During the same period in the previous year, the business posted $2.77 earnings per share. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities analysts anticipate that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio (DPR) is currently 61.97%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.